S&P 500 7718.60 -0.38%
NASDAQ 26506.99 -0.29%
TASI 11024.73 -0.40%
Oil (WTI) 91.48 +0.00%
Oil (Brent) 96.28 +0.00%
VIX 15.30 +5.30%
Gold 4476.60 +0.00%
USD/SAR 3.76 +0.02%

DexCom, Inc.

DXCM · Healthcare · · USD
87.90 USD
0.00 (-2.02%)
● Updated 2026-09-07 20:34 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score BUY Short-term (Swing)

77
/ 100
Technical 75
Trend & RS 95
Momentum 80
Fundamental (0%) 89
Macro 64
Liquidity 40
ComponentScoreWeight
Technical 75.0 40%
Trend & RS 95.2 20%
Momentum 79.9 20%
Fundamental 88.9 0%
Macro 64.4 15%
Liquidity 39.6 5%

Trade Setup

Entry 87.90
Stop Loss 82.92 (5.7%)
Target 1 (1:1) 92.88 (+5.7%)
Target 2 (2:1) 97.86 (+11.3%)
ATR(14) 2.49 (2.8%)
Risk per Share 4.98
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 19.3 -1.23
Momentum 79.9 +1.20
Quality 64.1 +0.57
Composite 54.5

Quality Scores

Piotroski F-Score 7 /9 — Strong
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score 16.53 Safe Zone
Distress <1.81Grey 1.81–2.99>2.99 Safe

Valuation vs Peers Overvalued

MetricStockSectorvs Peers
P/E Ratio 34.7 22.0 +58% above
P/B Ratio 12.7 4.0 Above

Comparing against Healthcare median multiples.

Trading at a premium to sector peers — verify growth justifies premium.

Intrinsic Value (DCF) Significantly Overvalued

Intrinsic Value
49.71
vs
Market Price
87.90
Upside
-43.4%
Margin of Safety -76.8%
Stage 1 PV (5yr FCF)4,272,061,808
Terminal Value PV14,486,327,377
Total Enterprise Value18,758,389,185

Assumptions

Base FCF763,778,188
Growth Rate (5yr)13.1%
Terminal Growth2.5%
Discount Rate (WACC)9.0%

2-stage DCF: 5yr projected FCF + Gordon Growth terminal value. Estimates only — adjust growth and WACC for your own assumptions.

Position Sizing — Kelly Criterion

4.5%
Recommended Size
49.66%
Full Kelly
24.83%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 77/100. Estimated win rate 63%, avg win 9.6%, avg loss 3.5%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

BEAR Regime: BEAR (20% confidence) — position size reduced 10%

Signal Summary STRONG BUY

3
Bullish Signals
1
Bearish Signals
52.92
RSI(14)
2.209
MACD

Relative Strength (RS) IMPROVING

87
/ 99
RS Rating
O'Neil PASS (≥80)
RS vs SPY ↑ RISING (+15.9% vs SPY 3M)
RS vs Sector OUTPERFORMING (Healthcare)
RS New High No (10d since high)
Sector Outperformance +12.9% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
IMPROVING: Gaining momentum — the stock is starting to outperform the market. Watch for RS new high confirmation.

Technical Indicators

IndicatorValueSignal
Rsi 52.92 NEUTRAL
Macd 2.209 BEARISH
Ma Cross 81.22 / 70.9 GOLDEN CROSS
Trend Short ABOVE SMA50
Trend Long ABOVE SMA200
Bollinger MIDDLE
Volume 0.58x NORMAL

Key Levels

LevelPrice
52-Week High92.59
Bollinger Upper92.2
SMA(200)70.9
SMA(50)81.22
SMA(20)89.89
Current Price87.90
Bollinger Lower87.58
52-Week Low54.11
ATR(14)2.49

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

MARKUP Confidence
100%
Acc: 0.0  |  Dist: 0.0  |  Markup: 2.0  |  Markdown: 0.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-08-31 Normal 0.74x Normal bar — no special VSA pattern
2026-09-01 Normal 0.53x Normal bar — no special VSA pattern
2026-09-02 Normal 0.47x Normal bar — no special VSA pattern
2026-09-03 Normal 0.41x Normal bar — no special VSA pattern
2026-09-04 No Demand 0.58x Low volume, narrow spread, weak close — no buying interest

Ichimoku Cloud NEUTRAL

LineValueStatus
Tenkan-sen (9) 89.93 Above Kijun
Kijun-sen (26) 86.05 Base line
Senkou A 87.99 Leading span A
Senkou B 79.94 Leading span B
Cloud 79.94 – 87.99 Bullish (Green)
Price vs Cloud 87.90 Inside Cloud
Chikou Span 83.45 Bullish
Alignment Score 3/4 NEUTRAL

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE ON 2 bars Momentum: BEARISH
BB: 87.58 – 92.2  |  KC: 86.33 – 93.45

Divergences (last 60 bars)

TypeIndicatorBars AgoStrength
Hidden Bullish RSI 8
Regular Bearish RSI 11

Anchored VWAP

VWAP: 69.92 Anchor: 2025-11-07 (52w Low) ABOVE AVWAP +25.7%

Heikin-Ashi Trend

BEARISH Full data via /api/advanced/DXCM

Valuation

MetricValue
Market Cap33.17B
P/E (TTM)34.74
Forward P/EN/A
P/B12.65
EPS2.53

Financial Health

MetricValue
Revenue Growth13.1%
Profit Margin20.1%
ROE38.5%
Debt/Equity53.35
Current Ratio1.73
Dividend YieldN/A
Payout RatioN/A
Beta1.42

Trading Data

87.90
Open
87.90
Day High
87.90
Day Low
2.36M
Volume (0.5x avg)

Recent News (8)

DexCom (DXCM) Stock Looks Undervalued On Fair Value While Earnings Look Fair
Simply Wall St. · 2026-09-04
Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks
StockStory · 2026-09-03
Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services
Barrons.com · 2026-09-03
3 Reasons DXCM Has Explosive Upside Potential
StockStory · 2026-09-01
Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth Today
Zacks · 2026-08-31
Analysts' Top S&P 500 Stocks to Buy Now
Kiplinger · 2026-08-27
The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?
24/7 Wall St. · 2026-08-27
Dexcom, Abbott await Medicare coverage expansion for CGMs
MedTech Dive · 2026-08-27

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —